$FEED

ENvue Medical, Inc.

ENvue Medical is a medical device company that develops, produces, markets and sells devices for enteral feeding. Its main product is the FDA 510(k)-cleared ENvue System, which uses electromagnetic navigation to help clinicians guide and monitor feeding-tube placement in hospitalized patients who need nutritional support. The system is used with dedicated disposable feeding tubes, sensors and other components. ENvue also sells enteral-feeding accessories, including syringes, and makes money through sales of the navigation system and recurring sales of disposable products. Its commercial efforts primarily target acute-care hospitals in the United States; ENfit-compatible syringes are also distributed through non-acute-care channels. The business operates through ENvue Medical Holdings LLC and NanoVibronix Ltd. NanoVibronix focuses on non-invasive medical devices for biofilm prevention and pain therapy designed for home use.

No enriched coverage for $FEED in the last 7 days.

No SEC Form 4 filings for $FEED in the last 30 days.

See all $FEED insider activity →
Low

A catheter device designed to reduce bacterial buildup is shipping to an exclusive UK and Ireland distributor.

ENvue Medical (OTC PINK:FEED) has begun shipping UroShield® catheters to its UK and Ireland distributor, Peak Medical, under a multi-year agreement with multi-million-dollar purchase commitments. This follows the September 2026 launch of PainShield® shipments in the U.S. Both products are now commercially available, marking a milestone in the company's U.S. manufacturing transition.

ENvue Medical, Inc. (FEED): Entry into a Material Definitive Agreement

ENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Secured Promissory Note and Security Agreement On October 8, 2026, ENvue Medical, Inc. (the “Company”) entered into a Secured Promissory Note and Security Agreement (the “Note and Security Agreement”) with Alpha Capital Anstalt

FEED sentiment & insider activity

Recent FEED coverage spans corporate actions, financial news and earnings.

What's driving FEED

  • First commercial shipments could lift the stock as revenue ramps up.

    stocktitan.net · Oct 29, 2026

  • ENvue Medical secured a $1M note from Alpha Capital, with $250K initially funded, to improve liquidity. The company also amended its Series X Preferred Stock terms, lowering the conversion price to $0.50 per share to support future financing, according to the company.

    tradingview.com · Oct 14, 2026

  • The new financing provides short‑term liquidity but adds debt at a 10% rate, potentially diluting equity if conversion occurs.

    SEC EDGAR 8-K · Oct 14, 2026

  • Visibility at a major conference could drive hospital sales and boost the stock.

    rttnews.com · Sep 4, 2026

  • The split reduced share count and lowered the price, pushing the stock toward its 52‑week low.

    investing.com · Sep 1, 2026

AlphAI scores every news story that mentions FEED with an AI model for sentiment and relevance, and aggregates insider trades from ENvue Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $FEED

Score

A catheter device designed to reduce bacterial buildup is shipping to an exclusive UK and Ireland distributor.

ENvue Medical (OTC PINK:FEED) has begun shipping UroShield® catheters to its UK and Ireland distributor, Peak Medical, under a multi-year agreement with multi-million-dollar purchase commitments. This follows the September 2026 launch of PainShield® shipments in the U.S. Both products are now commercially available, marking a milestone in the company's U.S. manufacturing transition.

$FEEDLowDebt financing· $1M

ENvue Medical, Inc. (FEED): Entry into a Material Definitive Agreement

ENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement Secured Promissory Note and Security Agreement On October 8, 2026, ENvue Medical, Inc. (the “Company”) entered into a Secured Promissory Note and Security Agreement (the “Note and Security Agreement”) with Alpha Capital Anstalt

$FEEDLowShareholder vote

ENvue Medical, Inc. (FEED): Submission of Matters to a Vote of Security Holders

ENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders. On August 14, 2026, ENvue Medical, Inc. (the “ Company ”) held a special meeting of stockholders (the “ Special Meeting ”). The final voting results of the Special Meeting are set forth below. Stockholders voted on t

$FEEDMedOffering· $50M · proposed

ENvue Medical, Inc. (FEED): Entry into a Material Definitive Agreement

ENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Committed Equity Facility of up to $50 million On August 12, 2026, ENvue Medical, Inc. (the “Company”) entered into a Common Shares Purchase Agreement (the “Purchase Agreement”), with an institutional investor (the “Investor”)

ENvue Medical, Inc.: ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

ENvue Medical (NASDAQ: FEED) said Zeev Rotstein, M.D. was appointed Chairman of the Board, replacing David Johnson, who and Nino Pionati are departing. ENvue also added Zvi Joseph and Lior Buchman as directors. The company cited Joseph’s AI governance background at Amdocs and Buchman’s $320 million in executed financings and M&A.

$FEEDLowExec change· appointed

ENvue Medical, Inc. (FEED): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

ENvue Medical, Inc. (FEED) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001326706 0001326706 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Related tickers